Long Haul COVID Clinical Trials

Find Long Haul COVID Clinical Trials Near You

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction (SHIELD)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• 18-65 years of age at the time of study entry

• Diagnosed with Long COVID

• Individuals of child-bearing potential must have a negative serum pregnancy test at screening and agree to on-site urine pregnancy testing at all subsequent study visits

• A urine drug screen performed at the Screening Visit must be negative for drugs of abuse such as methamphetamine, cocaine, phencyclidine (PCP), and non-disclosed amphetamines and opioids/opiates.

• Those with mild to moderate depression should be clinically stable for three months, without risk of suicidal ideation or behavior.

Locations
United States
New York
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE)
RECRUITING
New York
Contact Information
Primary
David Putrino, PhD
CoreResearch@mountsinai.org
212-241-7658
Time Frame
Start Date: 2026-10-20
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 150
Treatments
Experimental: Combination Drug Therapy
For 14 weeks, receives valacyclovir and celecoxib initially, then addition of Paxlovid for 25 days while decreasing valacyclovir dose, and then returns to valacyclovir at the original dose later.
Placebo_comparator: Placebo
For 14 weeks, receives matched placebo capsules and tablets
Related Therapeutic Areas
Sponsors
Collaborators: PridCor Therapeutics
Leads: Icahn School of Medicine at Mount Sinai

This content was sourced from clinicaltrials.gov